{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:40:19Z","timestamp":1794469219258,"version":"4.9.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ygyno.2024.07.006","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T23:14:59Z","timestamp":1721344499000},"page":"68-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA\/ENGOT-OV26\/GOG-3012"],"prefix":"10.1016","volume":"189","author":[{"given":"Mitchell R.","family":"Kamrava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gonzalez-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavana","family":"Pothuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"Graybill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor R.","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Freyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"York","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela A.","family":"Malinowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2024.07.006_bb0005","doi-asserted-by":"crossref","first-page":"38","DOI":"10.7150\/jca.49406","article-title":"Current ovarian cancer maintenance strategies and promising new developments","volume":"12","author":"Gogineni","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.ygyno.2024.07.006_bb0010","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13048-022-01020-1","article-title":"Maintenance therapy for newly diagnosed epithelial ovarian cancer- a review","volume":"15","author":"Nag","year":"2022","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.ygyno.2024.07.006_bb0015","series-title":"Niraparib [European Public Assessment Report]","author":"EMA","year":"2023"},{"key":"10.1016\/j.ygyno.2024.07.006_bb0020","series-title":"Niraparib [package insert]","author":"FDA","year":"2022"},{"key":"10.1016\/j.ygyno.2024.07.006_bb0025","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonzalez-Martin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2024.07.006_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.04.024","article-title":"Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer","volume":"189","author":"Gonzalez-Martin","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2024.07.006_bb0035","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.ygyno.2024.07.006_bb0040","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.21037\/jtd-22-536","article-title":"Oligoprogression in non-small cell lung cancer: a narrative review","volume":"14","author":"Nguyen","year":"2022","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.ygyno.2024.07.006_bb0045","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.clon.2019.05.015","article-title":"The dandelion dilemma revisited for oligoprogression: treat the whole lawn or weed selectively?","volume":"31","author":"Patel","year":"2019","journal-title":"Clin. Oncol. (R Coll Radiol)"},{"key":"10.1016\/j.ygyno.2024.07.006_bb0050","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ygyno.2023.04.002","article-title":"PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients","volume":"173","author":"Gauduchon","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.07.006_bb0055","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2022-003543","article-title":"Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance","author":"Palluzzi","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2024.07.006_bb0060","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1158\/1078-0432.CCR-16-2615","article-title":"Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: clinical and molecular characterization","volume":"23","author":"Lheureux","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2024.07.006_bb0065","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2024.07.006_bb0070","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.1200\/jco.2015.33.15_suppl.5532","article-title":"Use of homologous recombination deficiency (HRD) score to enrich for niraparib sensitive high grade ovarian tumors","volume":"33","author":"B.M","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.07.006_bb0075","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2024.07.006_bb0080","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2024.07.006_bb0085","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","article-title":"Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Shi","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2024.07.006_bb0090","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2024.07.006_bb0095","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2024.07.006_bb0100","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/IGC.0000000000001219","article-title":"Positive DESKTOP and tian scores systems are adequate to predict optimal (R0) secondary debulking surgery in ovarian cancer, but a negative score does not preclude secondary surgery","volume":"28","author":"Laga","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2024.07.006_bb0105","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1634\/theoncologist.2019-0309","article-title":"A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 study): A collaboration of MITO, AIRO GYN, and MaNGO groups","volume":"25","author":"Macchia","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2024.07.006_bb0110","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.eururo.2021.07.026","article-title":"Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: A phase 2 prospective multicenter study","volume":"80","author":"Cheung","year":"2021","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ygyno.2024.07.006_bb0115","article-title":"Stereotactic ablative radiotherapy for acquired resistance to EGFR therapy in metastatic non-small cell lung cancer","volume":"12","author":"Chicas-Sett","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ygyno.2024.07.006_bb0120","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41467-018-04278-6","article-title":"Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis","volume":"9","author":"Pitroda","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2024.07.006_bb0125","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jamaoncol.2023.2535","article-title":"Integrated clinical-molecular classification of colorectal liver metastases: A biomarker analysis of the phase 3 new EPOC randomized clinical trial","volume":"9","author":"Katipally","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2024.07.006_bb0130","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1136\/ijgc-2022-003435","article-title":"Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups","volume":"32","author":"Schettino","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2024.07.006_bb0135","doi-asserted-by":"crossref","first-page":"1164395","DOI":"10.3389\/fphar.2023.1164395","article-title":"Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer","volume":"14","author":"Dong","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ygyno.2024.07.006_bb0140","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1158\/1078-0432.CCR-22-3715","article-title":"Investigation of PARP inhibitor resistance based on serially collected circulating tumor DNA in patients with BRCA-mutated ovarian cancer","volume":"29","author":"Kim","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2024.07.006_bb0145","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1158\/1078-0432.CCR-23-0797","article-title":"Identifying mechanisms of resistance by circulating tumor DNA in EVOLVE, a phase II trial of cediranib plus olaparib for ovarian cancer at time of PARP inhibitor progression","volume":"29","author":"Lheureux","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2024.07.006_bb0150","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1136\/ijgc-2023-004605","article-title":"Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA\/ENGOT-ov26\/GOG-3012 trial: challenges and solutions","volume":"33","author":"Herzog","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2024.07.006_bb0155","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/oxfordjournals.annonc.a010602","article-title":"Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames ovary group study","volume":"7","author":"Rustin","year":"1996","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2024.07.006_bb0160","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ajog.2011.03.008","article-title":"Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations","volume":"204","author":"Salani","year":"2011","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2024.07.006_bb0165","doi-asserted-by":"crossref","first-page":"9338","DOI":"10.1200\/JCO.2005.02.2582","article-title":"Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range","volume":"23","author":"Santillan","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.07.006_bb0170","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.01182","article-title":"Poor concordance between cancer antigen-125 and RECIST assessment for progression in patients with platinum-sensitive relapsed ovarian cancer on maintenance therapy with a poly(ADP-ribose) polymerase inhibitor","author":"Tjokrowidjaja","year":"2024","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824003615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824003615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T14:43:48Z","timestamp":1728398628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824003615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":34,"alternative-id":["S0090825824003615"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.07.006","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA\/ENGOT-OV26\/GOG-3012","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}